These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 138101)

  • 61. Normal excretion of homovanillic acid in the urine of patients with Huntington's chorea.
    WILLIAMS CM; MAURY S; KIBLER RF
    J Neurochem; 1961 Feb; 6():254-6. PubMed ID: 13785404
    [No Abstract]   [Full Text] [Related]  

  • 62. Hyperglycemic chorea-ballism or acute exacerbation of Huntington's chorea? Huntington's disease unmasked by diabetic ketoacidosis in type 1 diabetes mellitus.
    Hashimoto K; Ito Y; Tanahashi H; Hayashi M; Yamakita N; Yasuda K
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3016-20. PubMed ID: 22745234
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Effect of administration of amino acids, especially of L-DOPA and -methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. 3. Alterations of cerebrospinal fluid in patients with Huntington's chorea after -methyldopa or L-DOPA].
    Simanyi M; Gerstenbrand F; Gründig E; Schedl R; Weiss H
    Z Neurol; 1973 Mar; 204(1):67-80. PubMed ID: 4121504
    [No Abstract]   [Full Text] [Related]  

  • 64. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.
    Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P
    J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Test for incipient Huntington's chorea.
    Cawein M; Turney F
    N Engl J Med; 1971 Mar; 284(9):504. PubMed ID: 4250751
    [No Abstract]   [Full Text] [Related]  

  • 66. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Juvenile Huntington's disease: a case report and literature review.
    Reyes Molón L; Yáñez Sáez RM; López-Ibor Alcocer MI
    Actas Esp Psiquiatr; 2010; 38(5):285-94. PubMed ID: 21117003
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Controlled trial of sodium valproate in severe epilepsy.
    Richens A; Ahmad S
    Br Med J; 1975 Nov; 4(5991):255-6. PubMed ID: 1104059
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Degradation of misfolded proteins by autophagy: is it a strategy for Huntington's disease treatment?
    Lin F; Qin ZH
    J Huntingtons Dis; 2013; 2(2):149-57. PubMed ID: 25063512
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Several biochemical mechanisms of the pathogenesis of Huntington chorea].
    Barkhatova VP; Larskiĭ EG; Markova ED; Ivanova-Smolenskaia IA; Insarova NG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(7):1038-45. PubMed ID: 6137919
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reserpine action in Huntington's chorea.
    Calabrese VP
    N Engl J Med; 1973 Jul; 289(2):104. PubMed ID: 4267988
    [No Abstract]   [Full Text] [Related]  

  • 73. Effects of dipropylacetic acid on late components of the photically evoked potential and afterdischarge in rat.
    Shearer DE; Fleming DE; Dustman RE
    Pharmacol Biochem Behav; 1978 Apr; 8(4):501-4. PubMed ID: 353820
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Investigation in the dipropylacetic acid series, C8 and C9 branched chain ethylenic acids and amides.
    Taillandier G; Benoit-Guyod JL; Laruelle C; Boucherle A
    Arch Pharm (Weinheim); 1977 May; 310(5):394-403. PubMed ID: 326226
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical pharmacological aspects of valproate sodium.
    Wulff K; Flachs H; Würtz-Jorgensen A; Gram L
    Epilepsia; 1977 Jun; 18(2):149-57. PubMed ID: 326543
    [No Abstract]   [Full Text] [Related]  

  • 76. Disposition of valproic acid in patients with liver disease.
    Klotz U; Rapp T; Müller WA
    Eur J Clin Pharmacol; 1978 Mar; 13(1):55-60. PubMed ID: 346355
    [No Abstract]   [Full Text] [Related]  

  • 77. Targeting Huntington's disease through histone deacetylases.
    Gray SG
    Clin Epigenetics; 2011 Aug; 2(2):257-77. PubMed ID: 22704341
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeting histone deacetylases for the treatment of Huntington's disease.
    Gray SG
    CNS Neurosci Ther; 2010 Dec; 16(6):348-61. PubMed ID: 20642797
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacology of epigenetics in brain disorders.
    Narayan P; Dragunow M
    Br J Pharmacol; 2010 Jan; 159(2):285-303. PubMed ID: 20015091
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
    Saft C; Lauter T; Kraus PH; Przuntek H; Andrich JE
    BMC Neurol; 2006 Feb; 6():11. PubMed ID: 16507108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.